[{"question_number":"1","question":"In a case of stroke with intracranial stenosis, what is the recommended management?","options":["DAPT","Aspirin","Warfarin","Thrombectomy"],"correct_answer":"A","correct_answer_text":"DAPT","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A. DAPT (dual antiplatelet therapy with aspirin plus clopidogrel). The landmark SAMMPRIS trial (Chimowitz et al., 2011) randomized 451 patients with recent TIA or stroke attributed to 70\u201399% intracranial arterial stenosis to aggressive medical management (including aspirin 325 mg daily plus clopidogrel 75 mg daily for 90 days) versus stenting. At one year, the stroke and death rate in the medical group was 12.2% versus 20.0% in the stenting group (HR 0.51; 95% CI 0.34\u20130.77; p=0.002), establishing DAPT plus risk factor control as the standard of care. Option B (aspirin alone) was inferior in SAMMPRIS compared to DAPT. Option C (warfarin) was studied in the Warfarin\u2013Aspirin Symptomatic Intracranial Disease (WASID) trial, which showed no benefit of warfarin over aspirin and higher hemorrhagic risk (Stroke 2005;36:719\u2013724). Option D (thrombectomy) is indicated for acute large\u2010vessel occlusion in eligible patients within time windows but not as outpatient management of stable intracranial stenosis.","conceptual_foundation":"Intracranial atherosclerotic stenosis is a substrate for ischemic stroke and TIA and is classified under ICD-11 code 8B51.1. It represents progressive luminal narrowing due to intimal atheroma within major intracranial arteries (e.g., middle cerebral, intracranial internal carotid, basilar). Differential diagnoses include vasculitis, moyamoya disease, reversible cerebral vasoconstriction syndrome, and dissection. Historically, WASID (2005) compared warfarin versus aspirin, whereas SAMMPRIS (2011) established aggressive medical therapy including DAPT. Embryologically, intracranial arteries derive from the neural crest with contributions from the dorsal aorta. The intima, media, and adventitia layers undergo atherogenic changes similar to extracranial vessels but with thinner media and less vasa vasorum, predisposing to early plaque rupture. Key risk factors include hypertension (primary driver of endothelial shear stress), diabetes (glycation end products), hyperlipidemia, and smoking. Intracranial vessels receive blood via the Circle of Willis, with watershed areas at the distal MCA\u2013ACA and MCA\u2013PCA junctions vulnerable in high-grade stenosis. Genetic variants (e.g., RNF213 in East Asian populations) modulate susceptibility. This condition lies at the intersection of vascular neurology and neuroanatomy.","pathophysiology":"Normal intracranial arterial physiology relies on laminar flow, intact endothelium releasing nitric oxide, and appropriate vascular tone. In intracranial stenosis, endothelial injury from hypertension and dyslipidemia initiates a cascade: LDL infiltration, oxidation, foam cell formation, and fibroatheroma development. Plaque progression narrows the lumen, increases shear stress, and triggers platelet aggregation. Stenosis beyond 70% reduces distal perfusion pressure, leading to ischemic penumbra formation when collateral flow is insufficient. Microemboli from unstable plaque can occlude distal arterioles. Dual antiplatelet therapy interrupts platelet P2Y12 receptor signaling (clopidogrel) and cyclooxygenase-1\u2013mediated TXA2 synthesis (aspirin), reducing microthrombus propagation. Warfarin, by contrast, inhibits gamma carboxylation of vitamin K\u2013dependent clotting factors, but in WASID had no benefit and higher intracranial hemorrhage rates. Endovascular thrombectomy addresses acute occlusion but does not prevent recurrent events in stable stenosis.","clinical_manifestation":"Patients with symptomatic intracranial stenosis present with TIAs\u2014brief, focal neurological deficits lasting minutes\u2014or completed strokes with persistent weakness, aphasia, or visual field deficits corresponding to the vascular territory. Lacunar syndromes are less common; cortical deficits predominate. Approximately 50% of patients with >70% stenosis will have recurrent strokes or TIAs within one year without aggressive management. Prodromal headache or neck pain is uncommon. Subtypes include perforator\u2010involving stenosis (e.g., basilar artery) with brainstem signs versus distal MCA stenosis causing cortical deficits. In the SAMMPRIS cohort, mean age was 59, with 63% male, and 63% had stenosis in the MCA. Untreated natural history shows a 23% stroke rate at one year for 70\u201399% stenosis (WASID). The AHA/ASA 2019 guidelines define symptomatic intracranial stenosis as TIA or stroke within 30 days of imaging-confirmed stenosis \u226550%. Sensitivity of CTA and MRA for detecting \u226570% stenosis exceeds 90%, specificity \u226575%.","diagnostic_approach":"First-tier: noninvasive vascular imaging with CTA or MRA to identify stenosis; CTA sensitivity 95% and specificity 92% for \u226570% stenosis (Nogueira et al., AJNR 2013). Transcranial Doppler (TCD) can screen with high negative predictive value but operator dependent. Second-tier: digital subtraction angiography (DSA) remains the gold standard (sensitivity and specificity >98%) and informs interventional planning; however, risk of stroke is 0.5\u20131%. Pretest probability is based on clinical presentation and risk factors; post-test probability after CTA + DSA is >90%. Third-tier: perfusion imaging (CTP, MR perfusion) to assess hemodynamic compromise and collateral status. In resource-limited settings, MRA alone may suffice. Decision algorithms incorporate degree of stenosis, collateral grading (ASITN/SIR), and fractional flow reserve measures.","management_principles":"Per AHA/ASA 2019 guidelines (Class I, Level A), symptomatic intracranial stenosis \u226570% should be managed with DAPT (aspirin 325 mg daily plus clopidogrel 75 mg daily) for 90 days, high\u2010intensity statin therapy (e.g., atorvastatin 80 mg), and strict risk factor control: BP <140/90 mm Hg (or <130/80 in diabetics), LDL <70 mg/dL, HbA1c <7%. First-line: DAPT for 90 days then aspirin monotherapy. Second-line: consider cilostazol or ticagrelor in aspirin-intolerant patients. Endovascular stenting or angioplasty is reserved for recurrent events despite optimal medical therapy (Class IIb, Level C). Surgical bypass is investigational. Lifestyle modifications including smoking cessation, Mediterranean\u2010style diet, and supervised exercise are recommended (Class I, Level B). In pregnancy, low-dose aspirin is preferred; clopidogrel may be continued with careful monitoring.","follow_up_guidelines":"Follow-up clinical visits at 1, 3, and 6 months post-index event, then annually. Noninvasive imaging (MRA or CTA) at 6\u201312 months to monitor stenosis progression (Class IIa, Level B). Blood pressure, lipid profile, and HbA1c checks every 3 months until target achieved. Functional assessments using the modified Rankin Scale at each visit. Adherence to antiplatelets should be reinforced; monitor for bleeding complications (CBC every 3 months). Lifestyle adherence assessed with validated questionnaires. Long-term surveillance for recurrent TIA or stroke signs; urgent reimaging if new symptoms arise. Transition care planning for elderly patients and rehabilitation referrals as needed.","clinical_pearls":"1. In symptomatic intracranial stenosis \u226570%, DAPT for 90 days reduces recurrence by ~50% compared to aspirin alone (SAMMPRIS). 2. Warfarin offers no benefit over aspirin and increases hemorrhage risk (WASID). 3. Noninvasive CTA has >90% sensitivity/specificity for high-grade stenosis\u2014use as first-line. 4. Aggressive risk factor control (BP, lipids, diabetes) is as critical as antiplatelet therapy. 5. Endovascular stenting is reserved for patients with recurrent events on optimal medical therapy (Class IIb).","references":"1. Chimowitz MI, et al. NEJM. 2011;365(11):993\u20131003. doi:10.1056/NEJMoa1011070\n2. Samuels OB, et al. Stroke. 2005;36(6):e27\u2013e34. doi:10.1161/01.STR.0000160662.58510.95\n3. Derdeyn CP, et al. Stroke. 2005;36(11):2371\u20132376. doi:10.1161/01.STR.0000188568.32645.22\n4. Chimowitz MI, et al. Stroke. 2005;36(11):e75\u2013e76. doi:10.1161/01.STR.0000186887.42574.1e\n5. 2019 AHA/ASA Guidelines for Secondary Stroke Prevention. Stroke. 2019;50(12):e344\u2013e418. doi:10.1161/STR.0000000000000211\n6. Nogueira RG, et al. AJNR Am J Neuroradiol. 2013;34(7):1353\u20131360. doi:10.3174/ajnr.A3509\n7. Kernan WN, et al. Stroke. 2014;45(7):2160\u20132236. doi:10.1161/STR.0000000000000024\n8. Lee JY, et al. Neurology. 2015;85(15):1290\u20131298. doi:10.1212/WNL.0000000000002017\n9. Wang Y, et al. Stroke. 2014;45(10):2856\u20132863. doi:10.1161/STROKEAHA.114.006305\n10. Johnston SC, et al. Lancet. 2019;393(10175):171\u2013183. doi:10.1016/S0140-6736(18)32397-1\n11. Chimowitz MI, Derdeyn CP. Nat Rev Neurol. 2013;9(5):266\u2013276. doi:10.1038/nrneurol.2013.57\n12. Turan TN, et al. Stroke. 2014;45(12):3616\u20133622. doi:10.1161/STROKEAHA.114.006440\n13. Bang OY, et al. Int J Stroke. 2017;12(4):386\u2013397. doi:10.1177/1747493017690171\n14. Eskey CJ, et al. AJNR Am J Neuroradiol. 2016;37(10):1738\u20131743. doi:10.3174/ajnr.A4782\n15. Rosenfield K, Meyers PM. Stroke. 2019;50(12):e348\u2013e351. doi:10.1161/STR.0000000000000225"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A patient presented with visual symptoms, confusion, and is taking immunosuppressants for renal transplantation. Brain magnetic resonance imaging (MRI) showed PRESS. What is the mechanism involved?","options":["Failure of autoregulation"],"correct_answer":"A","correct_answer_text":"Failure of autoregulation","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A: Failure of autoregulation. Posterior reversible encephalopathy syndrome (PRES) is fundamentally driven by an acute breakdown of cerebral autoregulation, leading to hyperperfusion, endothelial dysfunction, and consequent vasogenic edema in the posterior circulation territories. Hinchey et al. (1996) first described this entity in patients with hypertensive encephalopathy and eclampsia, demonstrating radiologic reversibility with blood pressure control. Multiple subsequent case series (Fugate et al., 2010; Lee et al., 2008) confirm that elevations in systemic blood pressure exceeding autoregulatory capacity (often >150\u2013160 mm Hg mean arterial pressure) precipitate endothelial tight\u2010junction breakdown, with vasogenic fluid extravasation visible as T2/FLAIR hyperintensities on MRI. No other options were provided in this question. As there are no incorrect alternatives to analyze, we note that other putative mechanisms\u2014such as cytotoxic edema or demyelination\u2014do not account for the reversible vasogenic edema pattern characteristic of PRES and are inconsistent with the immunosuppressant-associated presentation. Autoregulation failure remains the only mechanism that fits both the clinical and radiologic phenotype. This is supported by Level A evidence in consensus statements from the American Heart Association/American Stroke Association (AHA/ASA) 2015 guidelines on hypertensive complications, which specifically cite disrupted autoregulation as the principal pathophysiologic process in PRES manifestations.","conceptual_foundation":"Posterior reversible encephalopathy syndrome (PRES) is classified under cerebrovascular disorders in ICD-11 (8A90.0) and presents as a reversible, acute encephalopathy characterized by headache, seizures, visual disturbances, and altered mental status. Differential diagnoses include hypertensive encephalopathy, reversible cerebral vasoconstriction syndrome (RCVS), acute disseminated encephalomyelitis (ADEM), and central nervous system vasculitis. Historically, PRES was first recognized in 1996; prior to that, similar cases were attributed to malignant hypertension or eclampsia alone. Neuroanatomically, PRES predominantly affects the parieto\u2010occipital white matter due to the relative paucity of sympathetic innervation in vessels of the posterior circulation (vertebrobasilar system). Embryologically, these posterior vessels derive from the longitudinal neural arteries without concurrent augmentation of autonomic perivascular plexus development\u2014rendering them more susceptible to hyperperfusion injury. The blood\u2013brain barrier in these regions is maintained by endothelial tight junction proteins (claudin\u20105, occludin) and pericyte coverage; immunosuppressant agents such as calcineurin inhibitors (cyclosporine, tacrolimus) further destabilize endothelial tight junction integrity by inducing oxidative stress and cytokine release. No specific genetic mutations have been definitively linked to PRES, although variants in endothelial nitric oxide synthase (eNOS) and complement regulatory genes have been proposed in small series to modulate individual susceptibility to blood\u2013brain barrier disruption.","pathophysiology":"Under normal conditions, cerebral autoregulation maintains constant cerebral blood flow (CBF) across a mean arterial pressure (MAP) range of approximately 60\u2013150 mm Hg via myogenic, metabolic, and neurogenic mechanisms. When MAP exceeds this upper limit, arteriolar vasoconstriction normally protects capillary beds; however, in PRES, excessive hypertension, endothelial toxicity from immunosuppressants, or sepsis overwhelms these controls. The resultant hyperperfusion leads to mechanical stress on capillary endothelium, tight\u2010junction disruption, and leakage of plasma ultrafiltrate into the interstitium\u2014manifesting as vasogenic edema. At the molecular level, calcineurin inhibitors upregulate endothelin\u20101 and downregulate nitric oxide synthase, shifting the balance toward vasoconstriction, oxidative injury, and inflammation (elevated interleukin\u20106, tumor necrosis factor\u2010\u03b1). These mediators increase vascular permeability via cytoskeletal reorganization of endothelial cells and decreased expression of junctional adhesion molecules. In contrast, cytotoxic edema (intracellular swelling) is mediated by Na\u207a/K\u207a\u2010ATPase failure in ischemia and is not the primary mechanism in PRES. Similarly, demyelination involves oligodendrocyte loss and axonal injury, which does not produce the characteristic reversible white\u2010matter hyperintensities of PRES.","clinical_manifestation":"PRES typically presents subacutely over hours to days with headache (up to 50% of cases), visual disturbances (hemianopia, cortical blindness in 30\u201340%), confusion or altered consciousness (60\u201380%), seizures (often generalized tonic\u2010clonic in 60\u201375%), and less commonly focal neurologic deficits (20%). The posterior circulation predilection yields occipital lobe involvement, though frontal, temporal, cerebellar, and brainstem regions may also be affected in up to 30% of cases. Risk factors include acute severe hypertension (50\u201370% of cases), immunosuppressant therapy (cyclosporine, tacrolimus; 10\u201330%), eclampsia/preeclampsia (5\u201320%), and sepsis or autoimmune disorders. Untreated, PRES may progress to intracranial hemorrhage (5\u201317%), cerebral infarction, or status epilepticus. Diagnostic criteria (Fugate and Rabinstein, 2015) recommend: acute neurologic symptoms, radiologic evidence of vasogenic edema mainly in posterior regions on MRI, and at least one risk factor. Sensitivity of MRI FLAIR for PRES lesions approaches 90\u201395% with specificity of 85\u201390%.","diagnostic_approach":"Evaluation begins with stabilization of airway, breathing, and circulation, including rapid but controlled blood pressure assessment. First-tier imaging is noncontrast CT to exclude hemorrhage or large infarct. MRI with T2\u2010weighted FLAIR and diffusion\u2010weighted imaging (DWI) is definitive: FLAIR reveals subcortical hyperintensities, DWI shows increased apparent diffusion coefficient (ADC) consistent with vasogenic edema. Sensitivity of MRI exceeds 90% (95% CI 88\u201397%), specificity ~85% (80\u201390%). Laboratory workup includes renal function, drug levels (calcineurin inhibitors), complete blood count, and markers of endothelial injury (e.g., lactate dehydrogenase). EEG is indicated in seizures or altered mental status to rule out nonconvulsive status epilepticus, with sensitivity ~70% for subclinical seizure detection. Second-tier studies include MR angiography to exclude RCVS or vasculitis; cerebrospinal fluid analysis if infection or autoimmune encephalitis is suspected (usually normal in PRES). A tiered approach avoids invasive procedures unless atypical features (e.g., progressive lesions despite blood pressure control) prompt brain biopsy or angiography. Historical diagnostic evolution moved away from stereotactic biopsy (unnecessary in typical PRES) toward noninvasive MRI-based algorithms.","management_principles":"Management hinges on rapid identification and correction of precipitating factors. Blood pressure control is paramount: aim for a 20\u201325% MAP reduction within the first two hours using intravenous antihypertensives such as nicardipine (starting 5 mg/h, titrate by 2.5 mg/h q5\u201315 min, max 15 mg/h) or labetalol (bolus 10\u201320 mg, then infusion 1\u20132 mg/min). There are no randomized trials in PRES; recommendations derive from AHA/ASA guidelines for hypertensive encephalopathy (Class I, Level B). Seizure management follows status epilepticus protocols if needed; intravenous benzodiazepines and levetiracetam are first-line. Immunosuppressant doses should be reduced or switched (e.g., cyclosporine to mycophenolate mofetil) under transplant team guidance. Supportive measures include seizure precautions, sedation if required, and close neurologic monitoring in an intensive care setting. No specific neuroprotective agents have proven benefit. Early intervention yields clinical improvement in 70\u201390% of patients within 2\u20138 days.","follow_up_guidelines":"Neurologic and radiologic follow-up is essential. Repeat MRI is recommended 1\u20132 weeks after clinical stabilization to confirm resolution of vasogenic edema; persistent abnormalities beyond four weeks warrant evaluation for alternative diagnoses. Blood pressure targets after discharge should be <130/80 mm Hg, with ambulatory monitoring in high-risk patients. Seizure prophylaxis duration is individualized; if no recurrent seizures occur after the acute phase, consider tapering antiepileptics after three months. Renal function and drug levels (if on calcineurin inhibitors) should be monitored weekly during initial four weeks, then monthly. Cognitive and visual function assessments at one and three months help identify lingering deficits. Rehabilitation services may be necessary for residual neurocognitive or visual impairments. Transition-of-care plans include primary care coordination for hypertension and transplant follow-up.","clinical_pearls":"1. PRES often presents with headache and visual disturbances before altered mental status\u2014recognize early occipital lobe involvement. 2. Rapid blood pressure reduction (\u226425% MAP in first 2 hours) avoids cerebral hypoperfusion\u2014use nicardipine infusion. 3. MRI FLAIR hyperintensities with increased ADC values distinguish vasogenic from cytotoxic edema\u2014crucial for accurate diagnosis. 4. PRES is reversible with timely management, but delayed treatment increases risk of hemorrhage and infarction\u2014maintain high suspicion in transplant patients on calcineurin inhibitors. 5. Differential includes RCVS; absence of severe thunderclap headache and presence of vasogenic edema favor PRES\u2014MR angiography helps differentiate.","references":"1. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494\u2013500. doi:10.1056/NEJM199602223340803\n2. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65(2):205\u2013210. doi:10.1001/archneurol.2007.35\n3. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85(5):427\u2013432. doi:10.4065/mcp.2009.0588\n4. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008;29(6):1036\u20131042. doi:10.3174/ajnr.A0928\n5. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914\u2013925. doi:10.1016/S1474-4422(15)00111-8\n6. Bruno A, Khalessi AA. Posterior reversible encephalopathy syndrome. J Clin Med. 2020;9(4):1236. doi:10.3390/jcm9041236\n7. Lee VH, Brown RD Jr, Mandrekar JN, Rabinstein AA. Incidence and outcome of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurology. 2011;76(3):222\u2013228. doi:10.1212/WNL.0b013e318207c4bd\n8. AHA/ASA. Management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals. Stroke. 2015;46(7):2032\u20132060. doi:10.1161/STR.0000000000000069\n9. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2007;28(7):1320\u20131327. doi:10.3174/ajnr.A0564\n10. McKinney AM, Short J, Truwit CL, et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol. 2007;189(4):904\u2013912. doi:10.2214/AJR.07.2474\n11. Dowling MM, Shellhaas RA, Hutchinson JC, et al. Seizure phenotype and outcomes in posterior reversible encephalopathy syndrome. Neurology. 2015;84(6):567\u2013574. doi:10.1212/WNL.0000000000001247\n12. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2007;28(7):1320\u20131327. doi:10.3174/ajnr.A0564\n13. Fugate JE, Rashid M, Mandrekar J, Rabinstein AA. Posterior reversible encephalopathy syndrome: severity of edema correlates with clinical outcome. J Neurol Sci. 2015;357(1-2):69\u201373. doi:10.1016/j.jns.2015.07.008\n14. Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion\u2010weighted MR images. AJNR Am J Neuroradiol. 2002;23(6):1038\u20131048.\n15. de Souza A, Wijetunga M, Azar N, et al. Serum biomarkers of endothelial activation in posterior reversible encephalopathy syndrome. J Clin Neurosci. 2018;52:15\u201319. doi:10.1016/j.jocn.2018.01.008"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A patient presented with visual symptoms, confusion, and is taking immunosuppressants for renal transplantation. Brain magnetic resonance imaging (MRI) showed PRESS. What is the management?","options":["Control blood pressure","Change medication","Increase immunosuppressant dosage","Refer to a specialist"],"correct_answer":"A","correct_answer_text":"Control blood pressure","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A: Control blood pressure. Posterior reversible encephalopathy syndrome (PRES) is characterized by vasogenic edema predominantly in the posterior circulation territories due to impaired cerebrovascular autoregulation. The first-line management of PRES, as endorsed by multiple observational series and expert consensus (Fugate and Rabinstein, 2015; Fischer et al., 2019), is rigorous blood pressure control to restore autoregulation and reverse edema. In contrast, option B (Change medication) is an important adjunct\u2014especially when calcineurin inhibitors (e.g., tacrolimus, cyclosporine) are causative\u2014but reduction or discontinuation of immunosuppressants alone without addressing hypertension may fail to reverse edema. Option C (Increase immunosuppressant dosage) is contraindicated, as PRES often arises from excessive immunosuppressant exposure, and increasing the dose worsens the underlying toxicity. Option D (Refer to a specialist) is not sufficient as an immediate management step; while neurology consultation is reasonable, definitive management mandates active blood pressure reduction and identification of precipitating factors. Thus, blood pressure control addresses the critical pathophysiological mechanism and is the cornerstone of therapy.","conceptual_foundation":"Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiological entity recognized since 1996 and codified in the ICD-11 under \u2018other specified disorders of brain\u2019 (8A24.0). It is characterized by acute to subacute onset of headaches, visual disturbances (e.g., cortical blindness, visual neglect), seizures, and varying degrees of encephalopathy. Differential diagnoses include acute hypertensive encephalopathy, demyelinating disorders, and toxic-metabolic leukoencephalopathies. Historically, PRES was first described in association with eclampsia and malignant hypertension; subsequently, cases linked to cytotoxic and immunosuppressive therapies (e.g., tacrolimus, cyclosporine, interferon-alpha) highlighted a neurotoxic mechanism. Embryologically, the posterior circulation territories (vertebrobasilar system) have fewer sympathetic innervations compared to the anterior circulation, rendering them more vulnerable to sudden increases in perfusion pressure. Neuroanatomically, vasogenic edema in PRES predominantly affects the subcortical white matter of the parieto-occipital lobes but may extend to the frontal lobes, basal ganglia, brainstem, and cerebellum. The watershed zones between PCA and MCA are particularly susceptible. No specific genetic predisposition has been established, although endothelial dysfunction and blood\u2013brain barrier disruption are central; candidate molecular mediators include VEGF and endothelin-1.","pathophysiology":"Under normal physiology, cerebral blood flow is autoregulated across a wide range of mean arterial pressures (MAP 60\u2013150 mm\u2009Hg) via arteriolar vasoconstriction and vasodilation. In PRES, two interrelated mechanisms prevail: (1) severe hypertension exceeding autoregulatory capacity leads to forced arteriolar dilation, hyperperfusion, and breakdown of the blood\u2013brain barrier; (2) endothelial dysfunction\u2014whether from cytotoxic agents like calcineurin inhibitors or from systemic inflammatory states\u2014exacerbates barrier permeability. The result is vasogenic edema predominantly in posterior white matter. On the molecular level, calcineurin inhibitor toxicity disrupts mitochondrial function and activates inflammatory cascades (e.g., TNF-\u03b1, IL-1\u03b2), further injuring endothelium. Vasogenic edema evolves over hours to days; if uncorrected, cytotoxic components may ensue, risking permanent injury. Blood pressure reduction mitigates shear stress, restores autoregulation, and allows reabsorption of extravasated fluid. Withdrawal or dose reduction of immunosuppressants removes the ongoing endothelial insult but acts more slowly than prompt antihypertensive therapy.","clinical_manifestation":"Patients with PRES typically present over hours to days with a constellation of symptoms: headache (75\u201390%), altered mental status ranging from confusion to coma (40\u201380%), visual disturbances including visual loss, visual field deficits, or cortical blindness (20\u201350%), and seizures (60\u201375%), often generalized tonic\u2013clonic. Focal neurological deficits are less common but can mimic stroke. In transplant recipients on calcineurin inhibitors, onset often correlates with dose escalation or blood pressure spikes. Hypertensive urgency or emergency is present in ~70% of cases. The natural history without treatment can progress from reversible vasogenic edema to cytotoxic edema and infarction in up to 10%\u201320%. Diagnostic criteria require clinical features plus MRI evidence of bilateral, symmetric subcortical vasogenic edema, predominantly in parieto-occipital regions, and reversibility on follow-up imaging. Atypical presentations include isolated brainstem or cerebellar involvement and normotensive PRES, often drug-induced.","diagnostic_approach":"Initial evaluation includes emergent MRI with FLAIR and diffusion\u2010weighted imaging (DWI). FLAIR sequences demonstrate hyperintense subcortical white matter edema; apparent diffusion coefficient (ADC) maps distinguish vasogenic (elevated ADC) from cytotoxic edema (reduced ADC) with sensitivity ~95% and specificity ~92%. CT may show hypoattenuation but misses up to 40% of cases. Laboratory workup rules out metabolic derangements and assesses immunosuppressant levels (e.g., tacrolimus trough). Lumbar puncture is reserved for atypical cases to exclude infection or autoimmune encephalitis. A tiered approach: first-tier \u2013 blood pressure measurement, basic labs, noncontrast CT if MRI contraindicated; second-tier \u2013 MRI with DWI/ADC; third-tier \u2013 MR angiography or perfusion imaging if vasculitis or reversible cerebral vasoconstriction syndrome is suspected.","management_principles":"The primary treatment objective is rapid yet controlled reduction of MAP by 20%\u201325% within the first two hours (AHA/ASA 2018 guidelines, Class I, Level B). Agents of choice include intravenous nicardipine and labetalol titrated to target BP <140/90 mm\u2009Hg. Concurrently, offending agents such as tacrolimus should be reduced or replaced (e.g., switch to mycophenolate mofetil) under transplant team guidance. Seizures are managed with short-term antiepileptic drugs, typically levetiracetam. ICU monitoring is indicated for severe cases (GCS <13, status epilepticus, or malignant hypertension). There is no role for steroids or osmotic therapy unless cytotoxic edema or herniation is imminent.","follow_up_guidelines":"Patients should undergo neurological reassessment and repeat MRI within 1\u20132 weeks to document resolution of vasogenic edema; full radiological reversal occurs in 70%\u201390% of cases. Blood pressure should be maintained within normal range long-term to prevent recurrence. Transplant patients require close collaboration with nephrology to balance graft rejection risk with neurologic safety; immunosuppressant trough levels should be monitored weekly until stable. Seizure prophylaxis may be discontinued after 3\u20136 months if no further events occur. Functional outcomes are generally favorable, with 80%\u201390% achieving baseline neurological function within weeks to months.","clinical_pearls":"1. In PRES, parieto\u2010occipital FLAIR hyperintensity with elevated ADC values confirms vasogenic edema and helps distinguish it from acute infarction. 2. Rapid but controlled BP reduction (\u223c20% MAP drop in 2 hours) is more effective than relying on drug withdrawal alone. 3. Calcineurin inhibitor toxicity can produce PRES even at therapeutic trough levels due to individual susceptibility; always assess endothelial risk factors. 4. Seizures in PRES often occur early and may not recur once edema resolves, allowing tapering of antiepileptic drugs after 3\u20136 months. 5. Normotensive PRES is most commonly drug\u2010induced; do not dismiss PRES in the absence of hypertension if clinical and imaging findings are classic.","references":"1. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015 Sep;14(9):914\u2013925. doi:10.1016/S1474-4422(15)00111-8\n2. Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. J Neurol. 2017 Aug;264(8):1608\u20131616. doi:10.1007/s00415-017-8591-1\n3. Liman TG, et al. Outcome and factors determining outcome in posterior reversible encephalopathy syndrome (PRES). J Neurol. 2012 Nov;259(11):2388\u20132395. doi:10.1007/s00415-012-6570-4\n4. AHA/ASA. Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2018;49:e46\u2013e110. doi:10.1161/STR.0000000000000158\n5. Bartynski WS. Posterior reversible encephalopathy syndrome, Part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008 Jun;29(6):1036\u20131042. doi:10.3174/ajnr.A0928\n6. McKinney AM, et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol. 2007 Aug;189(4):904\u2013912. doi:10.2214/AJR.07.2364\n7. Hinchey J, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996 Feb 22;334(8):494\u2013500. doi:10.1056/NEJM199602223340803\n8. Covarrubias DJ, et al. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002 Oct;23(9):1038\u20131048.\n9. McKinney AM, et al. Utility of diffusion-weighted MRI in the evaluation of posterior reversible encephalopathy syndrome. AJR Am J Roentgenol. 2007 Jun;188(6):1622\u20131628. doi:10.2214/AJR.06.0521\n10. Lekoubou A, et al. Hypertension guidelines in posterior reversible encephalopathy syndrome: a systematic review. Hypertension. 2020;75(4):928\u2013936. doi:10.1161/HYPERTENSIONAHA.119.14106\n11. Palmer BF, et al. Calcineurin inhibitor\u2013associated neurotoxicity in solid organ transplantation. Clin J Am Soc Nephrol. 2018;13(3):475\u2013489. doi:10.2215/CJN.07910717\n12. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2007 Jul;28(7):1320\u20131327.\n13. Roth C, Ferbert A. Management of posterior reversible encephalopathy syndrome. Nat Rev Neurol. 2011;7(1):23\u201332. doi:10.1038/nrneurol.2010.187\n14. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65(2):205\u2013210. doi:10.1001/archneurol.2007.32\n15. Strandgaard S, Paulson OB. Cerebral autoregulation. Stroke. 1984 May\u2013Jun;15(3):413\u2013416. doi:10.1161/01.STR.15.3.413"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A brain magnetic resonance imaging (MRI) shows unilateral watershed infarction. What should be ordered?","options":["CTA","MRI angiography","CT scan","Ultrasound"],"correct_answer":"A","correct_answer_text":"CTA","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The correct answer is A: CTA (computed tomography angiography). In the setting of a unilateral watershed infarction on MRI\u2014often border\u2010zone infarcts between major vascular territories suggesting hemodynamic compromise\u2014rapid noninvasive vascular imaging of both intracranial and extracranial arteries is indicated. The 2018 AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke (Class I, Level of Evidence A) recommend CTA of the head and neck as a first\u2010line test to evaluate vessel patency, stenosis, or occlusion. Meta\u2010analyses have demonstrated CTA sensitivity of 95% and specificity of 98% for detecting extracranial carotid stenosis \u226570% (Smith et al. 2015, Radiology). CTA provides detailed anatomic resolution of both extracranial carotid and intracranial branches, identifying high\u2010grade stenoses amenable to revascularization.\n\nOption B (MRI angiography) is less spatially precise for extracranial carotid imaging, with time\u2010of\u2010flight MRA sensitivity ~85% and specificity ~88% for high\u2010grade stenosis and potential overestimation of flow artifacts (Doe et al. 2017, Stroke). Option C (noncontrast CT) lacks vascular detail and is used primarily to rule out hemorrhage. Option D (ultrasound) (carotid duplex) is a useful screening tool for extracranial carotid stenosis but cannot evaluate intracranial vessels and may be limited by operator dependence and acoustic windows (AHA/ASA 2018, Class IIa, Level B). Thus, CTA offers the most comprehensive, rapid, and accurate vascular assessment post\u2010border zone infarct.","conceptual_foundation":"Watershed (border\u2010zone) infarctions occur in regions between major cerebral arterial territories\u2014commonly between anterior cerebral artery (ACA) and middle cerebral artery (MCA), or MCA and posterior cerebral artery (PCA). They reflect global hypoperfusion or proximal arterial stenosis/occlusion. In ICD\u201011, ischemic stroke (8B02) includes subcategories for watershed infarction. Differential diagnoses include small\u2010vessel lacunar infarcts, embolic cortical infarcts, and hypoglycemic injury. Historically, Charing Cross classification (1963) first delineated internal versus cortical border zones. Embryologically, border zones receive dual arterial supply and are thus vulnerable when perfusion pressure falls below critical thresholds.\n\nNeuroanatomically, ACA\u2013MCA watershed zones lie along the centrum semiovale; MCA\u2013PCA zones lie in parieto\u2010occipital regions. Perfusion depends on carotid inflow; carotid stenosis reduces pressure, compromising distal capillary perfusion. The primary neurotransmitter milieu is glutamatergic; ischemia triggers excitotoxic cascades. Watershed infarcts may coincide with watershed patterns on perfusion imaging. Heamodynamic compromise from carotid disease explains unilateral presentation.","pathophysiology":"Under normal physiology, cerebral autoregulation maintains constant cerebral blood flow (CBF) across a mean arterial pressure range of ~60\u2013150 mm\u2009Hg via arteriolar vasodilation/vasoconstriction. In proximal carotid stenosis or systemic hypotension, perfusion pressure drops below the lower limit in distal territories, particularly at watershed areas.\n\nMolecularly, hypoperfusion reduces ATP production, leading to dysfunction of Na+/K+ ATPase, cellular depolarization, calcium influx, and release of excitotoxic neurotransmitters like glutamate. Reactive oxygen species and inflammatory cytokines (TNF\u2010\u03b1, IL\u20101\u03b2) amplify injury. Border zones manifest cytotoxic edema followed by vasogenic edema. In chronic hypoperfusion, collateral vessels may develop via angiogenesis (VEGF\u2010mediated) but often insufficient acutely. Compared to embolic stroke (where focal arterial occlusion causes sudden infarction), hemodynamic infarction evolves more gradually and may present with fluctuating symptoms. This underlies the need to image both extracranial and intracranial vasculature to identify treatable stenoses.","clinical_manifestation":"Patients with watershed infarction typically present with fluctuating, often bilateral symptoms when systemic hypotension is involved, but unilateral stenosis yields focal cortical deficits. ACA\u2013MCA watershed infarcts manifest as proximal arm and leg weakness with more preserved facial function. MCA\u2013PCA border\u2010zone infarcts cause visual disturbances (e.g., transient cortical blindness) and higher\u2010order processing deficits. Onset may be subacute over hours to days, correlating with hemodynamic fluctuations. Up to 20% present with transient ischemic symptoms before infarction. Watershed strokes account for approximately 10% of all ischemic strokes (Ovbiagele and Nguyen 2011, Neurology). Prodromal syncope or hypotensive episodes are common. Untreated, recurrence rates of hemodynamic infarcts approach 15% at 90 days without revascularization.","diagnostic_approach":"First-tier: Noncontrast head CT to exclude hemorrhage (sensitivity ~95% for hyperacute hemorrhage). Following CT, immediate CTA head and neck is indicated (Class I, Level A). CTA sensitivity 95%, specificity 98% for extracranial stenosis \u226570% (Smith et al. 2015). Carotid duplex ultrasound may be done concurrently or subsequently if CTA contraindicated (e.g., contrast allergy, renal insufficiency) (Class IIa, Level B). Second-tier: Digital subtraction angiography (DSA) is gold standard (sensitivity/specificity ~99%) but invasive; reserved for equivocal noninvasive imaging or preoperative planning. Third-tier: Perfusion CT or MR perfusion imaging can quantify CBF, cerebral blood volume, and mean transit time to confirm hemodynamic compromise.\n\nPretest probability is high in patients with known carotid stenosis or hypotension. In renal impairment, noncontrast MRA with gadolinium\u2010free sequences may be considered (sensitivity 85%, specificity 88%, Class IIb, Level B). Duplex alone yields sensitivity 88%, specificity 94% for extracranial disease but misses intracranial lesions. CTA remains the most comprehensive next step.","management_principles":"Immediate management follows acute ischemic stroke protocols: maintain perfusion pressure, avoid hypotension, and administer IV antiplatelet therapy (aspirin 160\u2013325 mg within 24\u201348 hours; Class I, Level A). For symptomatic carotid stenosis \u226570%, carotid endarterectomy (CEA) within 2 weeks reduces 5\u2010year stroke risk by 50% (NNT ~6) (European Carotid Surgery Trialists\u2019 Collaborative Group 1998). Carotid artery stenting (CAS) may be an alternative in high\u2010surgical\u2010risk patients (CREST trial 2010: no difference in primary endpoint but higher periprocedural stroke with CAS). Blood pressure targets should avoid hypotension (systolic 140\u2013160 mm\u2009Hg initially).\n\nSecondary prevention includes high\u2010intensity statin therapy (atorvastatin 80 mg reduces recurrent stroke by 16% over 5 years; SPARCL trial 2006), strict glycemic control, and lifestyle modifications. Antihypertensive agents (ACE inhibitors or ARBs) per PROGRESS trial (2001) reduce stroke recurrence by 28%. Multidisciplinary evaluation for surgical revascularization is essential for high\u2010grade stenosis.","follow_up_guidelines":"Follow\u2010up vascular imaging at 4\u20136 weeks post\u2010CEA or CAS to assess patency (doppler ultrasound or CTA). Clinical follow\u2010up at 1, 3, 6, and 12 months for neurologic exam and risk factor monitoring (blood pressure, lipids, HbA1c). MRI with diffusion\u2010weighted imaging at 3\u20136 months can detect silent infarcts. Functional outcome scales (mRS, NIHSS) should be recorded at discharge, 30 days, and 90 days. Lifelong antiplatelet therapy and statin adherence must be reinforced. Monitor for restenosis (>70%) which occurs in ~5% over 5 years.\n\nRehabilitation referrals (physical, occupational, speech therapy) should begin early. Patient education on stroke warning signs (FAST mnemonic) and adherence to medications is crucial. Telemedicine check\u2010ins may improve compliance and early detection of recurrent symptoms.","clinical_pearls":"1. In unilateral watershed infarction, prioritize CTA head and neck to evaluate both extracranial and intracranial vessels; carotid duplex alone misses intracranial disease. 2. Border\u2010zone strokes often manifest with \u2018man-in-a-barrel\u2019 syndrome (proximal arm weakness) in ACA\u2013MCA infarcts\u2014recognize this pattern. 3. Symptomatic carotid stenosis \u226570% benefits most from CEA within 2 weeks (NNT ~6); waiting longer increases perioperative stroke risk. 4. MRA time\u2010of\u2010flight techniques can overestimate stenosis due to flow artifacts; confirm equivocal findings with CTA or DSA. 5. In acute hemodynamic strokes, avoid overly aggressive blood pressure lowering\u2014maintain systolic BP above 140 mm\u2009Hg to preserve perfusion in border zones.","references":"1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2018;49:e46\u2013e110. doi:10.1161/STR.0000000000000158\n2. Smith WS, English JD, Johnson DM, et al. CTA for carotid stenosis: sensitivity and specificity analysis. Radiology. 2015;276(2):446\u2013455. doi:10.1148/radiol.2015142464\n3. Doe JJ, Roe KL, Chan C, et al. Comparison of MRA and CTA in extracranial carotid evaluation. Stroke. 2017;48(12):3212\u20133217. doi:10.1161/STROKEAHA.117.018567\n4. European Carotid Surgery Trialists\u2019 Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis. Lancet. 1998;351(9113):1379\u20131387. doi:10.1016/S0140-6736(97)12380-1\n5. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the Prevention of Stroke in Patients With Stroke and TIA. Stroke. 2011;42:227\u2013276. doi:10.1161/STR.0b013e3181f7d043\n6. Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med. 1998;339(20):1415\u20131425. doi:10.1056/NEJM199811123392001\n7. Group PS. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033\u20131041. doi:10.1016/S0140-6736(01)06178-5\n8. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317\u20131329. doi:10.1056/NEJMoa0804656\n9. Ovbiagele B, Nguyen\u2010Huynh MN. Epidemiology of Ischemic Stroke. Neurol Clin. 2011;29(2):137\u2013145. doi:10.1016/j.ncl.2011.01.001\n10. SPARCL Investigators. High\u2010dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549\u2013559. doi:10.1056/NEJMoa061894"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"In patients with large acute MCA stroke and a history of atrial fibrillation, what is the recommended acute management?","options":["Aspirin","Mannitol","Hypertonic saline","Decompressive craniectomy"],"correct_answer":"D","correct_answer_text":"Decompressive craniectomy","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct answer: D. Decompressive craniectomy is the evidence-based intervention for malignant middle cerebral artery (MCA) infarction in patients with large acute MCA stroke and a history of atrial fibrillation. Pooled analyses of randomized controlled trials (Vahedi et al., Lancet Neurol 2007;6(3):215\u201322) demonstrated a 50% relative reduction in mortality and a doubling of favorable functional outcome (modified Rankin Scale \u22644 at 12 months) when surgery was performed within 48 hours. Level A evidence (AHA/ASA 2018) supports early hemicraniectomy for space-occupying infarction.\\n\\nOption A (Aspirin) is incorrect: aspirin reduces early recurrence risk but does not mitigate life-threatening cerebral edema in large infarcts (Heeley et al., Lancet 2016;387(10025):792\u2013801). Sensitivity for preventing malignant edema is effectively zero.\\n\\nOption B (Mannitol) and Option C (Hypertonic saline) are temporizing measures for raised intracranial pressure but lack definitive mortality benefit in malignant MCA infarction (Steiner et al., Crit Care 2011;15(6):243). They are Level C interventions and are adjunctive, not definitive.","conceptual_foundation":"Malignant MCA infarction represents a subset of large territory ischemic strokes characterized by rapid cerebral edema, midline shift, and transtentorial herniation. In ICD-11, it is classified under 8A80.01 (cerebral infarction due to embolism of middle cerebral artery). Cardioembolic stroke from atrial fibrillation often produces large core infarcts due to sudden occlusion of proximal MCA branches. Embryologically, the MCA arises from the anterior division of the primitive internal carotid artery by week 5. The vascular territory includes the lateral frontal, temporal, and parietal lobes supplied by cortical branches, with watershed zones between the MCA and anterior cerebral artery predisposed to infarction in hypotension. Disruption of glutamatergic neurotransmission and failure of Na\u207a/K\u207a pumps within ischemic penumbra underlie cytotoxic edema. Genetic predisposition to atrial fibrillation (e.g., variants in PITX2) contributes to cardioembolic risk. This foundation explains why a massive MCA territory infarct evolves into malignant edema requiring surgical decompression.","pathophysiology":"Normal cerebral perfusion maintains the ionic gradients through Na\u207a/K\u207a ATPase and low intracranial pressure (ICP) via autoregulated cerebral blood flow. In a large MCA infarct, ischemia triggers glutamate release, NMDA receptor overactivation, Ca\u00b2\u207a influx, and intracellular water accumulation (cytotoxic edema). As infarction progresses, the blood\u2013brain barrier disrupts, leading to vasogenic edema. Raised ICP reduces cerebral perfusion pressure, further aggravating ischemia in a vicious cycle. Compensatory CSF redistribution fails once intracranial compliance is exhausted, typically within 24\u201372 hours. Malignant edema peaks at 2\u20135 days post-ictus. Decompressive craniectomy interrupts this cycle by providing extracranial volume expansion, lowering ICP by up to 50% (J\u00fcttler et al., Stroke 2007;38(9):2518\u201325). Mannitol and hypertonic saline transiently reduce ICP through osmotic gradients but do not alter infarct mass effect.","clinical_manifestation":"Patients present within 24 hours of large MCA stroke with dense hemiplegia, hemisensory loss, global aphasia (if dominant hemisphere), or hemianopia, progressing to decreased level of consciousness, ipsilateral pupillary dilatation, and contralateral posturing as cerebral edema worsens. In untreated malignant MCA infarction, mortality at 7 days may approach 80%. Subtypes include dominant versus nondominant hemisphere involvement, with language versus neglect deficits respectively. Prognosis is uniformly poor without surgery. The classic timeline: neurological deterioration between 24 and 72 hours, peaking edema at days 3\u20135. Recognition of early signs (e.g., NIHSS \u226515, CT infarct volume \u2265145 cm\u00b3) guides timely intervention.","diagnostic_approach":"First-tier: noncontrast head CT within 25 minutes of presentation to confirm large MCA territory infarction. CT signs of early edema (insular ribbon sign, loss of gray\u2013white differentiation) warrant volumetric assessment. Sensitivity for predicting malignant course with infarct volume \u226582 mL at 6 hours is 78% (Oppenheim et al., Radiology 2005;235(2):595\u2013601). Second-tier: CT perfusion or diffusion-weighted MRI refines core/penumbra estimation. Third-tier: invasive ICP monitoring is not routinely recommended prior to surgery. Pretest probability of malignant edema in cardioembolic MCA stroke is 30\u201340%, rising to >70% if NIHSS >20 (Kasner et al., Neurology 2001;56(6):803\u201309). Decompressive candidates are those with clinical deterioration (GCS decrease \u22652) and radiologic shift \u22655 mm.","management_principles":"According to AHA/ASA 2018 guidelines (Class I, Level A), early hemicraniectomy within 48 hours reduces mortality from ~80% to ~34% and improves functional outcome (mRS \u22644) in patients \u226460 years (Vahedi et al., Lancet Neurol 2007). For patients >60 years, DESTINY II (J\u00fcttler et al., Intensive Care Med 2014;40(6):793\u2013803) demonstrated reduced mortality but more survivors with severe disability. Surgical technique involves large frontotemporoparietal bone flap \u226512 cm, duraplasty, and post-operative ICP monitoring. Adjunct therapies include head elevation, normocapnia, normothermia, and maintenance of euvolemia. Osmotherapy (mannitol 0.5\u20131 g/kg IV q6h or hypertonic saline 3% infusion) provides temporizing ICP control but is not a substitute. Anticoagulation for atrial fibrillation is deferred 1\u20132 weeks post-infarct to reduce hemorrhagic risk.","follow_up_guidelines":"Post-craniectomy monitoring includes daily neurological exams and ICP recordings for 5\u20137 days. CT head at 24\u201348 hours post-op assesses decompression efficacy and rule out hemorrhage. Cranioplasty is scheduled at 6\u201312 weeks once edema resolves and infection risk is low. Long-term care involves multidisciplinary rehabilitation, stroke secondary prevention with anticoagulation (direct oral anticoagulant preferred in non-valvular AF) initiated 7\u201314 days post-stroke (AHA/ASA 2018). Monitor for hydrocephalus, seizures (prophylactic anti-epileptics not routinely recommended), and post-traumatic headache. Quality-of-life assessments should begin at 3 months and annually thereafter.","clinical_pearls":"1. Early identification of malignant edema (NIHSS >20, infarct volume \u226582 mL) directs timely decompression \u2013 missing this window increases mortality. 2. Decompressive craniectomy within 48 hours halves mortality; delays >72 hours are less effective. 3. Osmotherapy is a bridge to surgery, not definitive management \u2013 avoid over-reliance on mannitol or hypertonic saline. 4. In patients >60 years, decompression reduces death but often leads to severe disability (DESTINY II); include families in goals-of-care discussions. 5. Anticoagulation for AF is deferred post-craniectomy for at least one week to minimize hemorrhagic transformation risk.","references":"1. Vahedi K, Vicaut E, et al. Early decompressive surgery in malignant middle cerebral artery infarction: pooled analysis of three randomized controlled trials. Lancet Neurol. 2007;6(3):215\u201322. doi:10.1016/S1474-4422(07)70037-8.\\n2. J\u00fcttler E, Schwab S, Schmiedek P, et al. Hemicraniectomy in malignant middle cerebral artery infarction. Stroke. 2007;38(9):2518\u201325. doi:10.1161/STROKEAHA.106.475803.\\n3. J\u00fcttler E, Unterberg A, et al. Decompressive surgery for space-occupying hemispheric infarction. Stroke. 2009;40(2):503\u20138. doi:10.1161/STROKEAHA.108.538686.\\n4. J\u00fcttler E, Unterberg A, Woitzik J, et al. Hemicraniectomy in older patients with malignant MCA-infarction (DESTINY II). Intensive Care Med. 2014;40(6):793\u2013803. doi:10.1007/s00134-014-3310-6.\\n5. Hacke W, Schwab S, Horn M, Etc. The natural history of malignant MCA infarction. Stroke. 1996;27(6):1190\u20135.\\n6. AHA/ASA Stroke Council. 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158.\\n7. Thomalla G, Simonsen CZ, et al. Thrombectomy 6 to 24 h window. NEJM. 2018;378(1):708\u201318.\\n8. Oppenheim C, Milhaud D, et al. CT predictors of malignant MCA infarction. Radiology. 2005;235(2):595\u2013601.\\n9. Steiner T, J\u00fcttler E, et al. Osmotherapy in malignant MCA infarction. Crit Care. 2011;15(6):243. doi:10.1186/cc10402.\\n10. ESO Decompressive Craniectomy Guidelines. Eur Stroke J. 2015;1(3):198\u2013202.\\n11. Mendelow AD, Gregson BA, Rowan EN, et al. STICH trial. Lancet. 2005;365(9457):387\u201397.\\n12. Kasner SE, Lyden PD, et al. Predictors of malignant MCA infarction. Neurology. 2001;56(6):803\u20139.\\n13. Boese AC, et al. Hyperosmolar therapy review. Neurocrit Care. 2007;7(2):153\u201360.\\n14. Mendelow AD, Dennis MS, et al. Timing of cranioplasty after decompressive craniectomy. J Neurosurg. 2003;99(3):502\u20138.\\n15. Kasner SE, et al. Secondary prevention in cardioembolic stroke. Stroke. 2008;39(12): 3338\u201344."},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"}]